Articles related to CLINICAL TRIALS

MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

This phase 2 study underscores the challenges in enhancing therapeutic outcomes in metastatic castration-resistant prostate cancer with AZD4635 combined with immunotherapy, indicating a minimal PSA response among treated patients.

This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.

Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.